FOR IMMEDIATE RELEASE
Thursday, November 8th, 2001
CONTACT:
Floyd E. Bloom, M.D.
Founding Chief Executive Officer
(858) 677-0466
NEUROME, INC. ANNOUNCES DR. LESLIE
IVERSEN AS SECOND SCIENTIFIC ADVISORY BOARD MEMBER
LA JOLLA, CA – Neurome, Inc. announced today the appointment
of Leslie Iversen, Ph.D., as the second member of its Scientific
Advisory Board. Dr. Iversen, Professor of Pharmacology at
the Royal Postgraduate Medical School, Hammersmith Hospital
in London and Visiting Professor in the Department of Pharmacology
at the University of Oxford, is internationally recognized
for his fundamental contributions to the understanding of
neurotransmission and has linked his findings to the treatment
and diagnosis of schizophrenia and Alzheimer's disease. He
presently serves as Director of the Wolfson Center for Research
on Age Related Diseases at King's College in London.
“Leslie Iversen's discoveries of the actions of amino
acid, neuropeptide and classical neurotransmitters have been
the pioneering foundation for the discovery and development
of many medications,” said Dr. Floyd Bloom, Neurome's
chief executive officer. “He brings the kind of wisdom
that Neurome needs to interpret the discoveries that we hope
to make in our research program. We are delighted to have
Dr. Iversen join Tomas Hökfelt on our Scientific Advisory
Board.”
Dr. Iversen's principal areas of study include neurotransmitter
and neuropeptide mechanisms in the mammalian central nervous
system and the discovery and development of novel neuropharmalogical
agents.
“I welcome this opportunity to join Floyd Bloom, John
Morrison and Warren Young as they focus the Neurome Technologies
to document, for the post-genome, the molecular structure
of the brain,” said Iversen. “Their impressive
new platform will make possible a new generation of functional
exploration and understanding.
Dr. Iversen received his Ph.D. and B.A. from the University
of Cambridge. He was previously Vice President of Neuroscience
Research at Merck Research Laboratories and was Director of
the Neuroscience Research Center of Merck, Sharpe and Dohme
in the UK from 1983-1995. He was the Director of the Medical
Research Council, Neurochemical Pharmacology Unit in Cambridge,
England from 1970-1983. More recently, Dr. Iversen founded
Panos Therapeutics, where he serves as Director. Earlier this
year, the General Board at the University of Oxford reconfirmed
Dr. Iversen's title as Visiting Professor in Pharmacology
through 2003.
Dr. Iversen is a recipient of numerous awards, including
Fellow of the Royal Society of London and Foreign Associate
Member of the National Academy of Sciences in the United States.
He is the author of over 350 scientific publications.
Neurome, Inc. develops standardized, quantitative databases
that accurately depict and integrate gene expression patterns
in the three-dimensional context of the brain's structures,
circuits and cells, and deploys these databases in primary
research directed toward the discovery and development of
gene targets for enhancement of brain function and treatment
of brain-based disease. Neurome performs contract brain research
for pharmaceutical and biotechnology companies, while at the
same time pursuing its own in-house and collaborative research
protocols. The data collected from these efforts will populate
an evolving, comprehensive database available by subscription
and useful on a broad level for analyses of mouse models of
brain function and disease. In this regard, the application
of the Neurome technologies will provide rigorous, quantitative
data that are optimally suited to the measurement of subtle
cell-type specific shifts in gene expression, as well as progression
and prevention of degenerative events affecting specific cell
classes and brain regions.
For more information, please contact Neurome, Inc., 11149
North Torrey Pines Road, La Jolla, California 92037-1031.
Telephone: (858) 677-0466; Fax (858) 677-0458; Web site: www.neurome.com. |
